References
1. Amin P, Bryson T, Krall D, Levin L, Eckman J, Bernstein JA. Clinical
Characterization of Chronic Urticaria Phenotypes to Predict Treatment
Outcomes. Journal of Allergy and Clinical Immunology. 131(2):AB27.
2. Asero R, Cugno M, Tedeschi A. Eosinophils in chronic urticaria:
supporting or leading actors? The World Allergy Organization
journal. 2009;2(9):213-217.
3. Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest
developments in aetiology, diagnosis and therapy. Therapeutic
advances in chronic disease. 2015;6(6):304-313.
4. Amin P, Levin L, Holmes SJ, Picard J, Bernstein JA. Investigation of
patient-specific characteristics associated with treatment outcomes for
chronic urticaria. The journal of allergy and clinical immunology
In practice. 2015;3(3):400-407.
5. O’Donnell BF. Urticaria: impact on quality of life and economic cost.Immunology and allergy clinics of North America.2014;34(1):89-104.
6. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO
guideline for the definition, classification, diagnosis and management
of urticaria. Allergy. 2018;73(7):1393-1414.
7. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of
chronic idiopathic or spontaneous urticaria. N Engl J Med.2013;368(10):924-935.
8. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of
omalizumab in patients with chronic idiopathic/spontaneous urticaria who
remain symptomatic on H1 antihistamines: a randomized,
placebo-controlled study. The Journal of investigative
dermatology. 2015;135(1):67-75.
9. Horiuchi T, Weller PF. Expression of vascular endothelial growth
factor by human eosinophils: upregulation by granulocyte macrophage
colony-stimulating factor and interleukin-5. American journal of
respiratory cell and molecular biology. 1997;17(1):70-77.
10. Yu L, Buttgereit T, Stahl Skov P, et al. Immunological effects and
potential mechanisms of action of autologous serum therapy in chronic
spontaneous urticaria. J Eur Acad Dermatol Venereol.2019;33(9):1747-1754.
11. Kolkhir P, Andre F, Church MK, Maurer M, Metz M. Potential blood
biomarkers in chronic spontaneous urticaria. Clin Exp Allergy.2017;47(1):19-36.
12. Izaki S, Toyoshima S, Endo T, et al. Differentiation between control
subjects and patients with chronic spontaneous urticaria based on the
ability of anti-IgE autoantibodies (AAbs) to induce FcepsilonRI
crosslinking, as compared to anti-FcepsilonRIalpha AAbs. Allergol
Int. 2019;68(3):342-351.
13. Jain S. Pathogenesis of chronic urticaria: an overview.Dermatol Res Pract. 2014;2014:674709.
14. Caproni M, Giomi B, Volpi W, et al. Chronic idiopathic urticaria:
infiltrating cells and related cytokines in autologous serum-induced
wheals. Clin Immunol. 2005;114(3):284-292.
15. Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic urticaria: a focus
on pathogenesis. F1000Res. 2017;6:1095.
16. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of
mast cells in urticaria. Immunol Rev. 2018;282(1):232-247.
17. Caproni M, Volpi W, Macchia D, et al. Infiltrating cells and related
cytokines in lesional skin of patients with chronic idiopathic urticaria
and positive autologous serum skin test. Exp Dermatol.2003;12(5):621-628.
18. Bel EH, Ten Brinke A. New Anti-Eosinophil Drugs for Asthma and COPD:
Targeting the Trait! Chest. 2017;152(6):1276-1282.
19. Khorasanizadeh M, Eskian M, Assa’ad AH, Camargo CA, Jr., Rezaei N.
Efficacy and Safety of Benralizumab, a Monoclonal Antibody against
IL-5Ralpha, in Uncontrolled Eosinophilic Asthma. Int Rev Immunol.2016;35(4):294-311.
20. Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW.
Interleukin-5 pathway inhibition in the treatment of eosinophilic
respiratory disorders: evidence and unmet needs. Curr Opin Allergy
Clin Immunol. 2016;16(2):186-200.
21. Hawro T, Ohanyan T, Schoepke N, et al. The Urticaria Activity
Score-Validity, Reliability, and Responsiveness. The journal of
allergy and clinical immunology In practice. 2018;6(4):1185-1190 e1181.
22. Mathias SD, Dreskin SC, Kaplan A, Saini SS, Spector S, Rosen KE.
Development of a daily diary for patients with chronic idiopathic
urticaria. Ann Allergy Asthma Immunol. 2010;105(2):142-148.
23. Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating
the minimally important difference of the urticaria activity score and
other measures of disease activity in patients with chronic idiopathic
urticaria. Ann Allergy Asthma Immunol. 2012;108(1):20-24.
24. Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D.
Benralizumab for Chronic Spontaneous Urticaria. 2020;383(14):1389-1391.
25. Choi WS, Lim ES, Ban GY, et al. Disease-specific impairment of the
quality of life in adult patients with chronic spontaneous urticaria.Korean J Intern Med. 2018;33(1):185-192.
26. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the
impact of chronic urticaria on quality of life: chronic urticaria
quality of life questionnaire (CU-QoL). Allergy.2005;60(8):1073-1078.
27. Walsh KB, Zhang X, Zhu X, et al. Intracerebral Hemorrhage Induces
Inflammatory Gene Expression in Peripheral Blood: Global Transcriptional
Profiling in Intracerebral Hemorrhage Patients. DNA Cell Biol.2019;38(7):660-669.
28. Sharma M, Zhang X, Huang S. Integrate Imaging Flow Cytometry and
Transcriptomic Profiling to Evaluate Altered Endocytic CD1d Trafficking.J Vis Exp. 2018(140).
29. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice
junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-1111.
30. Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput
genomic analysis with Bioconductor. Nat Meth. 2015;12(2):115-121.
31. Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and
minimal important difference of the urticaria control test. J
Allergy Clin Immunol. 2017;140(6):1710-1713 e1711.
32. Snodgrass RG, Brune B. Regulation and Functions of 15-Lipoxygenases
in Human Macrophages. Front Pharmacol. 2019;10:719.
33. Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4
inhibits indoleamine 2,3-dioxygenase expression in human monocytes.Blood. 1994;83(5):1408-1411.
34. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an
anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo
for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging
study. Lancet Respir Med. 2014;2(11):879-890.
35. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of
chronic autoimmune urticaria with omalizumab. J Allergy Clin
Immunol. 2008;122(3):569-573.
36. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with
symptomatic chronic idiopathic/spontaneous urticaria despite standard
combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109.
37. Sabroe RA, Fiebiger E, Francis DM, et al. Classification of
anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic
urticaria and correlation with disease severity. J Allergy Clin
Immunol. 2002;110(3):492-499.
38. Xu H, Oriss TB, Fei M, et al. Indoleamine 2,3-dioxygenase in lung
dendritic cells promotes Th2 responses and allergic inflammation.Proc Natl Acad Sci U S A. 2008;105(18):6690-6695.
39. Pertovaara M, Hasan T, Raitala A, et al. Indoleamine 2,3-dioxygenase
activity is increased in patients with systemic lupus erythematosus and
predicts disease activation in the sunny season. Clin Exp
Immunol. 2007;150(2):274-278.
40. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M,
Fuchs D. Tryptophan degradation increases with stage in patients with
rheumatoid arthritis. Clin Rheumatol. 2006;25(3):334-337.
41. McGaha TL, Huang L, Lemos H, et al. Amino acid catabolism: a pivotal
regulator of innate and adaptive immunity. Immunol Rev.2012;249(1):135-157.
42. Scott GN, DuHadaway J, Pigott E, et al. The immunoregulatory enzyme
IDO paradoxically drives B cell-mediated autoimmunity. J Immunol.2009;182(12):7509-7517.
43. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a
drugable target to treat eosinophil and mast cell-associated conditions.Pharmacol Ther. 2012;135(3):327-336.
44. Mohamed RW, Fathy A, el-Sayed AE. Increased circulating
FcepsilonRII-bearing B-lymphocytes and serum levels of IL-4 in
non-autoreactive chronic idiopathic urticaria. Egypt J Immunol.2003;10(2):9-18.
45. Sandham DA, Barker L, Brown L, et al. Discovery of Fevipiprant
(NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for
Treatment of Asthma. ACS Med Chem Lett. 2017;8(5):582-586.